Bicalutamide

比卡鲁胺

Report date: 2026/02/28 20:00:37
NME

Base Information

Drug NameBicalutamide
Drug Alias Name卡他胺Bicalutamida比卡胺BicalutamidumCosudex +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAndrogen Receptor antagonists
TargetsAndrogen Receptor
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)HirsutismMetabolic Dysfunction-Associated Steatotic Liver Disease +[9] 
Global Approved IndicationsProstatic Neoplasms
Approved Indications in ChinaProstatic Neoplasms
Original Approved Country/TerritoryUnited Kingdom
Original Approved Date1995/02/23
Country/TerritoryCzechiaBelgiumCanada +[24] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesCanadian Institutes Of Health Research (Cihr)University Of California San FranciscoAstrazeneca Pharmaceutical Co Ltd +[8] 
Inactive CompaniesSandozAlessa Therapeutics IncUniversity Medical Center Groningen +[10] 
Active IndicationsMetabolic Dysfunction-Associated Steatotic Liver DiseaseUrinary Bladder NeoplasmsProstatic Neoplasms +[5] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)HirsutismGlioblastoma +[4] 

Other Information

ATC CodeL02BB03
Related LinksWikipediaDrugBankKEGG